Zimmer Biomet (ZBH) Competitors

Solventum (NYSE:SOLV) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations.

Do analysts recommend SOLV or ZBH?

Solventum currently has a consensus target price of $68.00, indicating a potential upside of 0.77%. Zimmer Biomet has a consensus target price of $123.22, indicating a potential upside of 9.49%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts clearly believe Zimmer Biomet is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zimmer Biomet	2 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.20

Does the media refer more to SOLV or ZBH?

In the previous week, Zimmer Biomet had 1 more articles in the media than Solventum. MarketBeat recorded 13 mentions for Zimmer Biomet and 12 mentions for Solventum. Zimmer Biomet's average media sentiment score of 1.09 beat Solventum's score of 0.57 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor SOLV or ZBH?

Zimmer Biomet received 898 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 67.24% of users gave Zimmer Biomet an outperform vote while only 5.88% of users gave Solventum an outperform vote.

Company	Underperform	Outperform
Solventum	Outperform Votes 1 5.88%	Underperform Votes 16 94.12%
Zimmer Biomet	Outperform Votes 899 67.24%	Underperform Votes 438 32.76%

Is SOLV or ZBH more profitable?

Zimmer Biomet has a net margin of 14.27% compared to Solventum's net margin of 0.00%. Zimmer Biomet's return on equity of 12.95% beat Solventum's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	N/A	N/A	N/A
Zimmer Biomet	14.27%	12.95%	7.55%

Do institutionals and insiders believe in SOLV or ZBH?

88.9% of Zimmer Biomet shares are owned by institutional investors. 1.0% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has better earnings & valuation, SOLV or ZBH?

Zimmer Biomet has higher revenue and earnings than Solventum.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	N/A	N/A	N/A	N/A	N/A
Zimmer Biomet	$7.39B	3.03	$1.02B	$5.26	21.40

Summary

Zimmer Biomet beats Solventum on 13 of the 13 factors compared between the two stocks.